<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00459628</url>
  </required_header>
  <id_info>
    <org_study_id>2007/009</org_study_id>
    <secondary_id>2007-002025-69</secondary_id>
    <secondary_id>SCIE2006-30</secondary_id>
    <secondary_id>ANI47</secondary_id>
    <nct_id>NCT00459628</nct_id>
  </id_info>
  <brief_title>Trial of Tomotherapy in Breast Cancer</brief_title>
  <acronym>TomoBreast</acronym>
  <official_title>Randomized Trial Comparing Conventional vs Short-course Reduced Volume Conformal Post-surgery Radiation Treatment in Women With Stage I or II Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vrije Universiteit Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vrije Universiteit Brussel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tomotherapy is a new radiation therapy system that uses an integrated CT scanner during
      delivery of radiation treatment to improve the accuracy of the treatment. Furthermore the
      irradiation is delivered helicoidally allowing highly conformal shaping of dose distribution.
      However the magnitude of the clinical advantage of using the system in breast cancer is
      unknown. The purpose of the present study is to investigate whether or not the Tomotherapy
      can substantially reduce pulmonary and cardiac toxicities, as compared with conventional
      radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prior to surgery: histological confirmation; medical imaging.

      Localizing markers are placed in case of breast conserving surgery.

      After surgery, patients are randomized to one of two treatment arms:

        -  Arm I: radiotherapy using tangential chest fields, and supraclavicular field in case of
           nodal involvement, according to our hospital's standard procedure (Voordeckers M et al,
           Radiother Oncol 2003;68:227 and 2004;70:225). Dose-fractionation: 50 Gy in 25 fractions
           over 5 weeks, 2 Gy/fraction. Additional boost 16 Gy in 8 fractions over 2 weeks if
           breast conserving surgery (verify marker/clip localization) and age &lt;= 70 years.

        -  Arm II: radiotherapy using the Tomotherapy system. Target area (breast, thorax wall,
           nodal areas) delimited according to pre-operative imaging and pathological description.
           Dose-fractionation (adapted from Whelan T et al, JNCI 2002;94:1143): 42 Gy in 15
           fractions over 3 weeks, 2.8 Gy/fraction. Simultaneous boost 0.6 Gy/fraction if breast
           conserving surgery.

      Physics quality control is integrated during treatment in both arms.

      Radiotherapy begins within 6 weeks after the last breast surgery. Concurrent or sequential
      adjuvant systemic treatments are allowed. In case of sequential adjuvant treatment with
      chemotherapy first, radiotherapy begins within 6 weeks after completion of the adjuvant
      chemotherapy.

      Quality of life, arm mobility and edema, pulmonary and heart function are assessed prior to
      radiotherapy, at 1-3 months after completion of radiotherapy, then yearly.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in pulmonary function and heart function tests</measure>
    <time_frame>From end of treatment up to 3 years after treatment</time_frame>
    <description>Assessment by pulmonary function tests and by heart echocardiography, compared with test values prior to treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local-regional recurrences.</measure>
    <time_frame>From end of treatment up to 15 years after treatment</time_frame>
    <description>Local-regional recurrences are assessed at time intervals as per the institution's standard practice for the clinical surveillance of patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Conventional radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional Long schedule Radiotherapy Arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tomotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Short course schedule by tomotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional radiotherapy</intervention_name>
    <description>Radiation treatment delivered by conventional linear accelerator using matching fields</description>
    <arm_group_label>Conventional radiotherapy</arm_group_label>
    <other_name>Arm I, Long schedule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Tomotherapy</intervention_name>
    <description>CT image guided intensity modulated radiation therapy delivered by the Tomotherapy HiArt system</description>
    <arm_group_label>Tomotherapy</arm_group_label>
    <other_name>Arm II, Short schedule, Helical Tomotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Histologically proven breast carcinoma

          -  Stage I or II (T1-3N0 or T1-2N1 M0, AJCC/TNM 6th edition)

          -  Surgery with clear margins

          -  Pre-operative medical imaging (at least CT, MRI, and/or PET-scan)

        Exclusion Criteria:

          -  Prior breast or thoracic radiotherapy

          -  Pregnancy or lactation

          -  Fertile patients without effective contraception

          -  Psychiatric or addictive disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark De Ridder, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Radiotherapy Department, Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vincent Vinh-Hung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiotherapy-Oncology, Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oncologisch Centrum, UZ Brussel</name>
      <address>
        <city>Jette</city>
        <state>Brussels</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Voordeckers M, Van de Steene J, Vinh-Hung V, Storme G. Adjuvant radiotherapy after mastectomy for pT1-pT2 node negative (pN0) breast cancer: is it worth the effort? Radiother Oncol. 2003 Sep;68(3):227-31.</citation>
    <PMID>13129629</PMID>
  </reference>
  <reference>
    <citation>Voordeckers M, Vinh-Hung V, Van de Steene J, Lamote J, Storme G. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol. 2004 Mar;70(3):225-30.</citation>
    <PMID>15064006</PMID>
  </reference>
  <reference>
    <citation>Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, Lada B, Lukka H, Perera F, Fyles A, Laukkanen E, Gulavita S, Benk V, Szechtman B. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002 Aug 7;94(15):1143-50.</citation>
    <PMID>12165639</PMID>
  </reference>
  <results_reference>
    <citation>Versmessen H, Vinh-Hung V, Van Parijs H, Miedema G, Voordeckers M, Adriaenssens N, Storme G, De Ridder M. Health-related quality of life in survivors of stage I-II breast cancer: randomized trial of post-operative conventional radiotherapy and hypofractionated tomotherapy. BMC Cancer. 2012 Oct 25;12:495. doi: 10.1186/1471-2407-12-495.</citation>
    <PMID>23098579</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Parijs H, Miedema G, Vinh-Hung V, Verbanck S, Adriaenssens N, Kerkhove D, Reynders T, Schuermans D, Leysen K, Hanon S, Van Camp G, Vincken W, Storme G, Verellen D, De Ridder M. Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial. Radiat Oncol. 2012 Jun 1;7:80. doi: 10.1186/1748-717X-7-80.</citation>
    <PMID>22656865</PMID>
  </results_reference>
  <results_reference>
    <citation>Adriaenssens N, De Ridder M, Lievens P, Van Parijs H, Vanhoeij M, Miedema G, Voordeckers M, Versmessen H, Storme G, Lamote J, Pauwels S, Vinh-Hung V. Scapula alata in early breast cancer patients enrolled in a randomized clinical trial of post-surgery short-course image-guided radiotherapy. World J Surg Oncol. 2012 May 16;10:86. doi: 10.1186/1477-7819-10-86.</citation>
    <PMID>22591589</PMID>
  </results_reference>
  <results_reference>
    <citation>Adriaenssens N, Vinh-Hung V, Miedema G, Versmessen H, Lamote J, Vanhoeij M, Lievens P, van Parijs H, Storme G, Voordeckers M, De Ridder M. Early contralateral shoulder-arm morbidity in breast cancer patients enrolled in a randomized trial of post-surgery radiation therapy. Breast Cancer (Auckl). 2012;6:79-93. doi: 10.4137/BCBCR.S9362. Epub 2012 Jul 30.</citation>
    <PMID>22904635</PMID>
  </results_reference>
  <results_reference>
    <citation>Verbanck S, Hanon S, Schuermans D, Van Parijs H, Vinh-Hung V, Miedema G, Verellen D, Storme G, Vanhoeij M, Lamote J, De Ridder M, Vincken W. Small airways function in breast cancer patients before and after radiotherapy. Breast Cancer Res Treat. 2012 Oct;135(3):857-65. doi: 10.1007/s10549-012-2201-7. Epub 2012 Aug 22.</citation>
    <PMID>22910929</PMID>
  </results_reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2007</study_first_submitted>
  <study_first_submitted_qc>April 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2007</study_first_posted>
  <last_update_submitted>May 12, 2017</last_update_submitted>
  <last_update_submitted_qc>May 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vrije Universiteit Brussel</investigator_affiliation>
    <investigator_full_name>Vincent Vinh-Hung, MD, PhD</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>early breast cancer</keyword>
  <keyword>post-operative radiation treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

